CRSP - Bluebird bio favored at Baird as sickle cell disease space gets busy
2023-08-24 15:42:35 ET
More on bluebird bio, CRISPR, etc.
- Vertex Pharmaceuticals Still Looks Attractive
- Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans
- Vertex Pharmaceuticals: Strategically Positioning For Future Success
- Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued
- Vertex/CRISPR, bluebird sickle cell therapies could be cost-effective - ICER
- CRISPR Therapeutics upgraded to buy at Citi on near-term approvals
- bluebird bio's lovo-cel won't have FDA advisory panel meeting
- Why did CRISPR Therapeutics stock soar today? Q2 results
For further details see:
Bluebird bio favored at Baird as sickle cell disease space gets busy